GPPAD-POInT (Global Platform of Autoimmune Diabetes - Primary Oral Insulin Trial)

计划入组 1,050 人 · 首次发布于 2017 年 12 月 7 日

Immune Effects of Oral Insulin in Relatives at Risk for Type 1 Diabetes Mellitus (TN20)

计划入组 92 人 · 首次发布于 2015 年 10 月 20 日

A Euglycemic Insulin Clamp Study in Type 1 Diabetic Patients With Oral Insulin (ORAMED)

计划入组 11 人 · 首次发布于 2015 年 8 月 31 日

Oral insulin(Orin Pharmaceuticals)

Oral insulin-338-C10

Oramed Pharmaceuticals

United States

Oral-B Laboratories

United States

Philips Oral Healthcare

United States

Oramed Advances Oral Insulin Program with New U.S. Trial Following Subgroup Analysis

Oramed Pharmaceuticals Advances Oral Insulin Program with New Phase 3 Trial

Natural Polymers Emerge as Promising Platform for Advanced Insulin Delivery Systems